Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
Saved in:
| Title: | Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib. |
|---|---|
| Authors: | Prokoph N; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Matthews JD; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Trigg RM; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Montes-Mojarro IA; Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany., Burke GAA; Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Fend F; Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany., Merkel O; Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria., Kenner L; Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.; Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria.; Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria.; Center for Biomarker Research in Medicine (CBmed) Vienna, Core-Lab2, Medical University of Vienna, Vienna, Austria., Geoerger B; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France.; INSERM U1015, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France., Johnston R; Department of Paediatric Oncology/Haematology, Royal Belfast Hospital for Sick Children, Belfast, UK., Murray MJ; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Riguad C; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France., Brugières L; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France., Turner SD; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic. |
| Source: | British journal of haematology [Br J Haematol] 2023 Sep; Vol. 202 (5), pp. 985-994. Date of Electronic Publication: 2023 Jun 25. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2141 |
|---|---|
| DOI: | 10.1111/bjh.18953 |
